De-risking innovative drug development through
efficacy-focused preclinical services
De-risking innovative drug development through
efficacy-focused preclinical services
Chengdu Acer Biosciences Co., Ltd.
Company Profile
Chengdu Acer Biosciences Co., Ltd. is a premier preclinical Contract Research Organization (CRO) dedicated to de-risking and accelerating innovative drug development.
We address the critical industry bottleneck where insufficient efficacy accounts for approximately 60% of clinical trial failures through integration of essential upstream and downstream technologies, resources, and talent to build an international, large-scale, and standardized third-party preclinical efficacy evaluation platform.
Our service portfolio spans druggability assessment,efficacy evaluation,bio-analysis and advanced formulation optimization. We empower our clients to make right decision and accelerate product commercialization based on high-quality data.
Since 2024 when we put into operation, we serviced up to 200 clients, some projects were authorized by FDA IND approval.
Facility Scale
Acer Biosciences Preclinical Drug Efficacy Evaluation Base, covering approximately
building area of nearly
High-standard laboratory animal facilities: approximately
Bio analysis and molecular imaging platforms: approximately
Capacity for innovative drug efficacy evaluation
Early safety assessment capacity
Our Leadership
Li Wang
Chief Scientist, Chairman of the Scientific Committee; Scientific Advisor of Acer Capital
Guangji Wang
Advisor to the Scientific Committee
Xu Bao
Member of the Scientific Committee
Yongping Qin
Member of the Scientific Committee
Man Cho
Chairman
Dr. Yuan Yu
Executive General Manager & Member of the Scientific Committee
Shaohui Cai
Chief Technology Officer & Member of the Scientific Committee
Qiong Tang
Chief Marketing Officer
Gang Ai
Assistant General Manager
Qualification
2026.01
Member Unit — Sichuan Laboratory Animal Society
2026.1
CNAS Accreditation Certificate
2025
Chengdu High-tech Zone Pilot Platform
2023.12
Sichuan Brain-Computer Interface Engineering Research Center
2024.01
January 2024: Obtained the Sichuan Province Biosafety Level 2 Laboratory Filing Registration Certificate for Pathogens Infecting Humans.
2023.11
Chengdu Tianfu International Bio-Town Public Technical Service Platform Designation — Preclinical Efficacy & Advanced Formulation Evaluation Center
2023.09
Obtained the Laboratory Animal Use License.
Animal Welfare
We regard laboratory animal welfare as the core ethics of scientific research and the foundation of data quality. We strictly follow the AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care, International) accreditation requirements and relevant regulations such as the "Regulations on the Management of Laboratory Animals" to build a systematic animal welfare management system.
Our independent Institutional Animal Care and Use Committee (IACUC) provides full-process oversight based on the 3R principles (Replacement, Reduction, Refinement). Through rigorous protocol reviews, facility inspections, veterinary monitoring, and pain management training, we ensure our animals enjoy the Five Freedoms: freedom from hunger and thirst; freedom from discomfort; freedom from pain, injury, and disease; freedom from fear and distress; and freedom to express normal behaviour.
